Sándor Dedeyne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sándor Dedeyne has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- An Hendrix
Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium
21 shared publications - Olivier De Wever
Cancer Research Institute Ghent, Ghent University, Ghent, Belgium
21 shared publications - Amélie Vander Cruyssen
Laboratory of Experimental Cancer Research Department of Human Structure and Repair Ghent University Ghent Belgium
20 shared publications - Felix De Vuyst
Ghent University 1 Laboratory of Experimental Cancer Research, Department of Human Structure and Repair Ghent, Belgium
20 shared publications - Jyrki Heino
InFLAMES Research Flagship, Åbo Akademi University and University of Turku, Turku, Finland
20 shared publications - Ligia Craciun
Division CMP, Cerba Path, Brussels, Belgium
20 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Integrated sc-RNA sequence associated metadata
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Integrated sc-RNA sequence associated metadata
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Antibodies for WB, IF, and IHC
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Antibodies for WB, IF, and IHC
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
MEK1/2 inhibition mediates a phenotypic shift towards a myCAF subtype.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
MEK1/2 inhibition mediates a phenotypic shift towards a myCAF subtype.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Primer sequences of qRT-PCR and list of siRNAs
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Primer sequences of qRT-PCR and list of siRNAs
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
CAF phenotypic switching induced by pharmacological targeting of key signaling nodes in vitro and ex vivo.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
CAF phenotypic switching induced by pharmacological targeting of key signaling nodes in vitro and ex vivo.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Normal fibroblasts vs CAFs differentially expressed genes
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Normal fibroblasts vs CAFs differentially expressed genes
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Compound and recombinant cytokines
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Compound and recombinant cytokines
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
PI3K/mTOR inhibition induces iCAF phenotype through FGF2/FGFR pathway activation.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
PI3K/mTOR inhibition induces iCAF phenotype through FGF2/FGFR pathway activation.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
ROCK and interferon signaling cooperate to regulate MEK1/2 inhibitor-mediated actomyosin contractility.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
ROCK and interferon signaling cooperate to regulate MEK1/2 inhibitor-mediated actomyosin contractility.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Cancer-associated fibroblasts (CAF) exhibit phenotypic heterogeneity with each functional state playing critical roles in tumor progression. Notably, subtypes like inflammatory CAFs (iCAF), characterized by increased chemokine/cytokine secretion, and myofibroblast-like CAFs (myCAF), characterized by enhanced extracellular matrix (ECM) deposition and increased actomyosin contractility, can undergo phenotypic switching in response to cues from the tumor microenvironment and therapeutic interventions. Elucidation of the signaling pathways associated with the diverse phenotypes could enable development of strategies to therapeutically reprogram CAFs. Through the analysis of single-cell RNA sequencing data from patients with colorectal cancer, we identified that the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways, among other pathways, are linked to the formation of myCAF and iCAF subtypes, respectively. Unbiased pharmacologic interference of 12 distinct signaling pathways using three-dimensional (3D) human colorectal cancer–derived CAF cultures, ex vivo patient-derived tumor fragments, and mouse models further revealed the significance of PI3K/mTOR and MAPK/ERK signaling in CAF plasticity and functional behavior. PI3K/mTOR inhibition drove iCAF formation through compensatory FGF2 release and FGFR1–JAK2–STAT3 activation, leading to chemokine/cytokine secretion that promoted tumor spheroid growth and neutrophil infiltration. Conversely, MEK inhibition induced a myCAF phenotype via interferon-dependent ROCK and JAK1 signaling, resulting in ECM production that enhanced tumor colony formation. In summary, these findings reveal a functional significance of PI3K/mTOR and MAPK/ERK signaling pathways in CAF plasticity and underscore how standard-of-care targeted therapies can directly influence CAF phenotypes in colorectal cancer.Significance:The PI3K/mTOR and MAPK/ERK signaling pathways regulate the formation of CAF subtypes in colorectal cancer, providing insights into how fibroblasts adapt to cancer-targeted therapies and potential strategies to harness stromal plasticity.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
Cancer-associated fibroblasts (CAF) exhibit phenotypic heterogeneity with each functional state playing critical roles in tumor progression. Notably, subtypes like inflammatory CAFs (iCAF), characterized by increased chemokine/cytokine secretion, and myofibroblast-like CAFs (myCAF), characterized by enhanced extracellular matrix (ECM) deposition and increased actomyosin contractility, can undergo phenotypic switching in response to cues from the tumor microenvironment and therapeutic interventions. Elucidation of the signaling pathways associated with the diverse phenotypes could enable development of strategies to therapeutically reprogram CAFs. Through the analysis of single-cell RNA sequencing data from patients with colorectal cancer, we identified that the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways, among other pathways, are linked to the formation of myCAF and iCAF subtypes, respectively. Unbiased pharmacologic interference of 12 distinct signaling pathways using three-dimensional (3D) human colorectal cancer–derived CAF cultures, ex vivo patient-derived tumor fragments, and mouse models further revealed the significance of PI3K/mTOR and MAPK/ERK signaling in CAF plasticity and functional behavior. PI3K/mTOR inhibition drove iCAF formation through compensatory FGF2 release and FGFR1–JAK2–STAT3 activation, leading to chemokine/cytokine secretion that promoted tumor spheroid growth and neutrophil infiltration. Conversely, MEK inhibition induced a myCAF phenotype via interferon-dependent ROCK and JAK1 signaling, resulting in ECM production that enhanced tumor colony formation. In summary, these findings reveal a functional significance of PI3K/mTOR and MAPK/ERK signaling pathways in CAF plasticity and underscore how standard-of-care targeted therapies can directly influence CAF phenotypes in colorectal cancer.Significance:The PI3K/mTOR and MAPK/ERK signaling pathways regulate the formation of CAF subtypes in colorectal cancer, providing insights into how fibroblasts adapt to cancer-targeted therapies and potential strategies to harness stromal plasticity.